Genfit wins BTD status at FDA for its lead drug for liver disease; Idorsia outlines $530M '19 spending plans on late-stage R&D
→ Genfit $GNFT is getting a helping hand from the FDA with its lead drug elafibranor, in development for primary biliary cholangitis, a liver disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
